FORT WORTH, Texas--(BUSINESS WIRE)--Alcon Laboratories, Inc., a subsidiary of Alcon, Inc. (NYSE:ACL), announced today that the U.S. Food and Drug Administration (FDA) has granted approval of the AcrySof® ReSTOR® apodized diffractive aspheric intraocular lens for the visual correction of aphakia following cataract surgery in adult patients with and without presbyopia. The AcrySof® ReSTOR® apodized diffractive aspheric intraocular lens is the only FDA-approved presbyopia-correcting intraocular lens that incorporates aspheric optics into its design. Alcon will begin a phased commercial launch of this new lens after necessary consignment quantities are established, with full distribution expected by the middle of the year.
# # #
About Alcon
Alcon, Inc. is the world's leading eye care company with sales of $4.4 billion in 2005. Alcon, which has been dedicated to the ophthalmic industry for more than 60 years, develops, manufactures and markets pharmaceuticals, surgical equipment and devices, contact lens care solutions and other vision care products that treat diseases, disorders and other conditions of the eye. For more information on Alcon, Inc., visit the Company's Web site at www.alcon.com.
Michigan Eye Institute is a leading regional eye care center, offering complete optical, medical and surgical eye services in Flint, Fenton, Lapeer, Grand Blanc and Oxford. All Doctors are Board Certified. State-of-the-art facilities accomadate every aspect of primary and specialty eye care.
